Lemborexant (Dayvigo) is a dual orexin receptor antagonist studied for insomnia. It acts on wake-promoting orexin signaling. The research below distinguishes observed findings from interpretation.[1.1]
Selected human research: SUNRISE 2 analyzed 949 treated adults with insomnia, comparing oral lemborexant 5 or 10 mg with placebo over six months. Both doses improved self-reported sleep onset, overnight wakefulness, sleep efficiency and sleep quality versus placebo at month six. Most adverse events were mild or moderate; serious events were uncommon and no deaths occurred. Sleep diaries were used. The following six months had active treatment only, so this is not a 12-month placebo-controlled comparison.[2.1]
Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal.
No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.
SUNRISE 2 analyzed 949 treated adults with insomnia, comparing oral lemborexant 5 or 10 mg with placebo over six months.
Demonstrated findings
Both doses improved self-reported sleep onset, overnight wakefulness, sleep efficiency and sleep quality versus placebo at month six. Most adverse events were mild or moderate; serious events were uncommon and no deaths occurred.
What might this mean? · interpretation
This supports sustained improvement in patient-reported insomnia outcomes during the controlled period.
What might this mean, and what would change the interpretation?
Sleep diaries were used. The following six months had active treatment only, so this is not a 12-month placebo-controlled comparison.
What would clarify this: Longer controlled follow-up and functional outcomes.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
1,006 adults aged 55–88 with insomnia. Lemborexant 5 or 10 mg, zolpidem extended release 6.25 mg, or placebo at bedtime for one month.
Demonstrated findings
Both lemborexant doses improved the primary sleep-onset measure versus placebo. Secondary overnight wake time improved by 24.0 and 25.4 minutes versus placebo. Second-half-of-night wake time improved by 6.7 and 8.0 minutes versus zolpidem.
Limitations & adverse findings
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
What might this mean? · interpretation
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
More about Lemborexant: identity, safety & reference details
Small moleculeSleep & insomnia
Primary research area
Sleep · insomnia
Regulatory status
See compound-specific sources
Evidence level
Human research · indication-specific
Primary mechanism
See the source-linked compound overview
Reference profile available · Coverage varies by section
Also known as Dayvigo · E2006
What has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewed
Does Dayvigo’s sleep benefit persist for six months?
SUNRISE 2 analyzed 949 treated adults with insomnia, comparing oral lemborexant 5 or 10 mg with placebo over six months.
Both doses improved self-reported sleep onset, overnight wakefulness, sleep efficiency and sleep quality versus placebo at month six. Most adverse events were mild or moderate; serious events were uncommon and no deaths occurred.
Limits: Sleep diaries were used. The following six months had active treatment only, so this is not a 12-month placebo-controlled comparison.
Does Dayvigo help people fall asleep and stay asleep?
1,006 adults aged 55–88 with insomnia. Lemborexant 5 or 10 mg, zolpidem extended release 6.25 mg, or placebo at bedtime for one month.
Both lemborexant doses improved the primary sleep-onset measure versus placebo. Secondary overnight wake time improved by 24.0 and 25.4 minutes versus placebo. Second-half-of-night wake time improved by 6.7 and 8.0 minutes versus zolpidem.
Limits & adverse findings: One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia. One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
The research below distinguishes observed findings from interpretation. [1]
Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia. [1]
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia.
Human study: One-month trial, predominantly women. No treatment-related serious adverse events were reported; most other events were mild or moderate. These results do not establish benefit in people without insomnia. Source
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Identity, names & formulations
Canonical compound: Lemborexant · lemborexant
Searchable names: Dayvigo, E2006
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Reference facts checked 2026-09-23. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.